TC Medical(SH:600763) SINOLINK SECURITIES·2025-08-24 08:01Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of 5% to 15% over the next 6 to 12 months [3][9]. Core Insights - The company achieved stable revenue growth in H1 2025, with total revenue of 1.448 billion RMB, a year-on-year increase of 2.68%, and a net profit attributable to shareholders of 321 million RMB, up 3.66% year-on-year [1]. - The orthodontics segment showed strong performance, generating 229 million RMB in revenue, reflecting a year-on-year growth of 7.75%, continuing the recovery trend from Q1 [1][2]. - The company's operational model, combining regional hospitals and branch hospitals, has shown significant expansion, with 89 medical institutions and over 4,452 medical professionals [2]. - The integration of AI technology into clinical diagnosis and operational management has enhanced efficiency, positioning the company competitively in the market [2]. Summary by Sections Performance Review - In H1 2025, the company reported revenue of 1.448 billion RMB, with a net profit of 321 million RMB, and a non-recurring net profit of 317 million RMB [1]. - In Q2 2025, revenue was 703 million RMB, with a net profit of 137 million RMB, showing a slight year-on-year increase of 0.24% [1]. Business Analysis - The orthodontics business is recovering well, while the implant business remained stable with revenue of 255 million RMB, showing a minimal year-on-year change of 0.02% [1]. - Pediatric business revenue decreased by 1.48% to 236 million RMB [1]. Growth Strategy - The company operates 89 medical institutions and employs 4,452 medical professionals, with a medical space exceeding 260,000 square meters [2]. - The "medical + technology" strategy is being deepened, leveraging AI to improve operational efficiency and clinical decision-making [2]. Profit Forecast and Valuation - The company is projected to achieve net profits of 537 million RMB, 574 million RMB, and 610 million RMB for the years 2025, 2026, and 2027, respectively, with expected growth rates of 7%, 6.82%, and 6.35% [3][7]. - The estimated EPS for the same years is 1.20, 1.28, and 1.36 RMB, with corresponding PE ratios of 39, 36, and 34 times [3].